Categories
Blood Cancer

Epigenetic mechanisms driving the progression of MDS to secondary AML [Video]

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China talks on the various mechanisms which drive the progression of myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (AML). Dr Gill outlines the two most common mutational profiles seen in patients with MDS who progress to secondary AML – the accumulation of genes which confer a proliferative advantage and the acquisition of mutations in tumor suppressor genes. Dr Gill also comments on how the treatments patients with MDS receive may also contribute to the progression, for instance hypomethylating agents (HMAs) potentially inducing epigenetic changes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Colon Cancer

Identification and targeting of rare genomic alterations in metastatic CRC [Video]

Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA, talks on the use of next-generation sequencing (NGS) and RNA sequencing (RNA-Seq) to identify the molecular makeup of colorectal cancer (CRC). The potential to target rare genomic alterations present in metastatic CRC, for instance NTRK fusions, is discussed. Moreover, Prof. Lenz comments on the development of KRAS-G12C and KRAS-G12D inhibitors and the discrepancies in success rates of using these drugs for the treatment of other cancers, such as non-small cell lung cancer (NSCLC), compared to colorectal cancer (CRC). This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Categories
Blood Cancer

TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS [Video]

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the rationale and results of TakeAim Leukemia, a Phase I/IIa dose escalation and cohort expansion study evaluating the safety and clinical activity of the IRAK4 inhibitor emavusertib alone or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (NCT04278768). Overall, the agent showed a promising activity in this patient population, especially in patients with splicing mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Fixed-duration vs continuous therapy in CLL [Video]

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, compares defined duration versus continuous therapy in chronic lymphocytic leukemia (CLL), commenting on the possibility of finding biomarkers to define the length and intensity of treatment for each patient, and highlighting promising results from the HOVON-141/VISION trial (NCT03226301). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Phase II study of camidanlumab tesirine in R/R Hodgkin lymphoma [Video]

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the rationale, design, and results of a Phase II study investigating the clinical efficacy and tolerability of the antibody-drug conjugate (ADC) camidanlumab tesirine in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have been treated with brentuximab vedotin and PD-1 inhibitors (NCT04052997). The study reported a promising activity with a long-lasting response, and showed that camidanlumab tesirine did not have an impact on subsequent transplant efficacy. In addition, patients experienced primarily hematological toxicities as well as Guillain-Barré syndrome (GBS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Pancreatic Cancer

Does exposure to a magnetic field increase responses to radiotherapy? [Video]

Luca Nicosia, MD, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, explains a preclinical study which investigated whether exposure to a magnetic field affected responses to radiotherapy. The study used 4 cell lines, made up of organoids derived from patients with pancreatic cancer. The cell lines were treated with either magnetic field alone, radiotherapy alone, magnetic field plus radiotherapy, or nothing. The study reported that concomitant exposure to a magnetic field plus radiotherapy increased apoptosis of tumor cells in the cell cultures. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.

Categories
Blood Cancer

The impact of TP53 mutations in patients with myelofibrosis undergoing SCT [Video]

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, highlights the results of the first study that provides evidence on TP53 mutations for transplant and non-transplant settings in myelofibrosis (MF). He underscores that genotype and phenotype did not play a role in patients with or without TP53 mutations, but in TP53-mutated patients post-transplant acute myeloid leukemia (AML) was more frequent. In addition, allele frequency played an important role in overall survival (OS) and relapse-free survival (RFS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Patient risk stratification in CLL and selection of treatment approaches [Video]

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses patient risk stratification in chronic lymphocytic leukemia (CLL), drawing focus on the role of TP53 mutation, del(17p), and IgHV mutational status, and how these prognostic factors influence treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Breast Cancer

Stereotactic body radiotherapy and concomitant systemic therapy for oligoprogressive breast cancer [Video]

Luca Nicosia, MD, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, explains a study on patients with oligoprogressive breast cancer treated with stereotactic body radiotherapy (SBRT) and concomitant systemic therapy. The study explored the effectiveness of SBRT in delaying the time to next systemic treatment (NEST) in patients treated with SBRT during the first or second treatment cycle. It was found that SBRT delayed NEST by a median time of 8 months. Multivariate analysis found that the number of treated oligometastases was a significant factor in determining NEST. Importantly, patients with more than one oligometastatic legion had a significantly shorter NEST so patients with only one metastasis are likely to benefit the most from SBRT. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.

Categories
Blood Cancer

Exploring the potential of CAR-T therapy in CLL [Video]

Despite the initial promise of CAR-T therapy in chronic lymphocytic leukemia (CLL), clinical success has been limited so far. In this session chaired by John Gribben, MD, DSc, FRCPath, FMed Sci, Barts and The London School of Medicine, Queen Mary University of London, London, UK, Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA and Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, discuss some of the barriers to CAR-T therapy in CLL, exploring the role of CAR-T therapy in CLL and debating the optimal time to use this strategy in patients. Moving forward, the experts comment on the financial advantages associated with the use of CAR-T therapy over BTK inhibitors and move on to discuss the differences between CD28 and 4-1BB CAR-T constructs, questioning the importance of CAR-T persistence in CLL. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.

Categories
Pancreatic Cancer

CodeBreak100: assessing sotorasib in patients with KRAS p.G12C-mutant pancreatic cancer [Video]

KRAS mutations are present in 90% of pancreatic ductal adenocarcinomas (PDACs). P.G12C accounts for 1-2% of these KRAS mutations. John H. Strickler, MD, Duke Cancer Institute, Durham, NC, provides an overview of the international, single-arm, Phase I/II trial, CodeBreak100 (NCT03600883) exploring the KRAS p.G12C inhibitor, sotorasib, in patients with previosuly treated pancreatic cancer harboring the KRAS p.G12C mutation. The primary endpoint is confirmed objective response rate (ORR) and secondary endpoints include duration of response (DoR), progression-free survival (PFS) and overall-survival (OS). 38 patients with pancreatic cancer received sotorasib once daily. ORR was 21.1% and DCR was 84.2%, with a PFS of 4 months and median DoR of 6 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.